FindTrial
Sign In

Toripalimab (JS001 )

DRUG4 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., West China Hospital, Tianjin First Central Hospital

Conditions

Hepatocellular CarcinomaNon Muscle Invasive Bladder CancerUrinary Bladder NeoplasmsUrothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter

Phase 1

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
TerminatedNCT03867370
Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma
Start: 2019-04-26End: 2023-08-08Updated: 2023-11-29

Phase 2

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
RecruitingNCT06823427
Mabwell (Shanghai) Bioscience Co., Ltd.Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent +1
Start: 2025-01-17End: 2027-06-30Target: 60Updated: 2025-03-21
HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
Not yet recruitingNCT07608224
West China HospitalUrinary Bladder Neoplasms
Start: 2026-06-20End: 2030-12-31Target: 240Updated: 2026-05-27
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
Not yet recruitingNCT07808216
Tianjin First Central HospitalNon Muscle Invasive Bladder Cancer
Start: 2026-10-01End: 2031-10-01Target: 54Updated: 2026-09-08

Related Papers

Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC)
Cancer Research2021-07-0119 citations